Clinical Trial

DALY II Japan/MB-CART2019.1 for DLBCL

Study acronym: DALY II Japan
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
DALY II Japan is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-03; most recent amendment 2026-01-06.
Status change: Not Yet Recruiting → Recruiting 2026-01-06
Trial Details
NCT Number NCT07288879
Lead Sponsor Miltenyi Biomedicine GmbH
Conditions DLBCL - Diffuse Large B Cell Lymphoma, CAR T Cell Therapy
Enrollment 31 participants
Start Date 2025-12-11
Primary Completion 2027-01-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-08